Dupilumab for chronic spontaneous urticaria-marvelous or meek?

Autor: Mathur SK; Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wis. Electronic address: skmathur@wisc.edu., Rosenberg DL; Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wis., Viswanathan RK; Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wis.
Jazyk: angličtina
Zdroj: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2024 Jul; Vol. 154 (1), pp. 91-93. Date of Electronic Publication: 2024 May 14.
DOI: 10.1016/j.jaci.2024.05.004
Abstrakt: Competing Interests: Disclosure statement Disclosure of potential conflict of interest: S. K. Mathur received consulting and speaker fees from Astra-Zeneca, GSK, Sanofi, and Regeneron. D. L Rosenberg and R. K. Viswanathan report no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: